Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.

Abacavir is a nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy in HIV-1-infected patients. Because this drug can cause a hypersensitivity reaction that is correlated with the presence of the HLA-B*57:01 allotype, screening for the presence of HLA-B*57:01...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Ward De Spiegelaere, Jan Philippé, Karen Vervisch, Chris Verhofstede, Eva Malatinkova, Maja Kiselinova, Wim Trypsteen, Pawel Bonczkowski, Dirk Vogelaers, Steven Callens, Jean Ruelle, Kabamba Kabeya, Stephane De Wit, Petra Van Acker, Vicky Van Sandt, Marie-Paule Emonds, Paul Coucke, Erica Sermijn, Linos Vandekerckhove
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Public Library of Science (PLoS) 2015-01-01
Seri Bilgileri:	PLoS ONE
Online Erişim:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0123525&type=printable
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.

Benzer Materyaller